T he role of topoisomerase inhibitors in gynaecological oncology

Reviews in Gynaecological Practice

Volumn 2, Issue 1-2, 2002, Pages 29-34

  Hall, Geoffrey D ^a   Perren, Timothy J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Carcinoma of the cervix; Chemotherapy; Ovarian cancer; Topoisomerase inhibitors

Indexed keywords

ATROPINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PLATINUM; TOPOTECAN;

ALOPECIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CELL DEATH; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DNA REPLICATION; DOSE RESPONSE; DRUG EFFICACY; ENTEROPATHY; ENZYME BLOOD LEVEL; FATIGUE; FLUSHING; GYNECOLOGIC CANCER; HUMAN; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OVARY CANCER; REVIEW; RHINITIS; SALIVATION DISORDER; SIDE EFFECT; STOMATITIS; SWEATING; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 15944370974     PISSN: 14717697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-7697(02)00004-7     Document Type: Review

References (50)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6.
2. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18(1):106-15.
3. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3 years results. J Natl Cancer Inst 2000;92(9):699-708.
4. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol 1999;17(5):1339-48.
5. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340(15):1137-43.
6. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340(15):1144-53.
7. Keys HM, Bundy BN, Stehman EB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340(15):1154-61.
8. Buxton EJ, Meanwell CA, Hilton C, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81(5):359-61.
9. Wang JC. DNA topoisomerases. Ann Rev Biochem 1996;65:635-92.
10. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260(27):14873-8.
11. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49(18):5077-82.
12. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994;303(Pt 3):681-95.
13. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996;379(6562):225-32.
14. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31(2):85-102.
15. Burris III HA, Hanauske AR, Johnson RK. Activity of topotecan: a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84(23):1816-20.
16. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31(3):229-39.
17. Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14(4):1224-35.
18. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183-93.
19. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodynamics of 21 days topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy: New York gynecologic oncology group. J Clin Oncol 1999;17(8):2553-61.
20. Rose PG, Gordon NH, Fusco N, et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000;78(2):228-34.
21. O'Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14(12):3062-73.
22. Schellens JH, Creemers GJ, Beijnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73(10):1268-71.
23. Gerrits CJ, Burris H, Schellens JH, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 1998;34(7):1030-5.
24. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38(1):57-63.
25. Lhomme C, Fumoleau P, Fargeot P, et al. Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17(10):3136-42.
26. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11: a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991;83(16):1164-8.
27. Gordon A, Fleagle J, Guthrie D. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22.
28. Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11(11): 2194-204.
29. Miller AA, Hargis JB, Lilenbaum RC, et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 1994;12(12):2743-50.
30. Lilenbaum RC, Ratain MJ, Miller AA, et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol 1995;13(9):2230-7.
31. O'Reilly S, Fleming GF, Barker SD, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a gynecologic oncology group study. J Clin Oncol 1997;15(1):177-86.
32. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol 2000;23(3):297-300.
33. Cacciari N, Zamagni C, Martoni A. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer: is it possible only with peripheral blood stem cell support. Eur J Gynaecol Oncol 2000;21(1):84-5.
34. Frasci G, Panza N, Comella P, et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 1999;10(3):355-8.
35. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12(1):60-3.
36. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69(1):191-5.
37. Rose PG, Blessing JA, Van Le L, Waggoner S. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 1998;16(2):405-10.
38. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 1998;27(5):650-6.
39. Adachi S, Ogasawara T, Yamasaki N, et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 1999;29(9):434-7.
40. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15(2):625-31.
41. Irvin WP, Price FV, Bailey H. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 1998;82(2):328-33.
42. Sugiyama T, Yakushiji M, Noda K, et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000;58(1):31-7.
43. Morris M, Brader KR, Burke TW, Levenback CF, Gershenson DM. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol Oncol 1998;70(2):215-8.
44. Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a gynecologic oncology group study. Am J Clin Oncol 2000;23(4):355-7.
45. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16(10):3345-52.
46. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14(12): 3056-61.
47. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2000;18(5): 1062-7.
48. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5 days infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14(5):1552-7.
49. Markman M, Blessing JA, Alvarez RD, et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2000;77(1):112-5.
50. Markman M, Blessing JA, DeGeest K. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a gynecologic oncology group trial. Gynecol Oncol 1999;75(3):444-6.